Back to Search Start Over

Long-Term Noninvasive Ventilation in the Geneva Lake Area: Indications, Prevalence, and Modalities.

Authors :
Cantero C
Adler D
Pasquina P
Uldry C
Egger B
Prella M
Younossian AB
Soccal PM
Pépin JL
Janssens JP
Source :
Chest [Chest] 2020 Jul; Vol. 158 (1), pp. 279-291. Date of Electronic Publication: 2020 Mar 31.
Publication Year :
2020

Abstract

Background: Noninvasive ventilation (NIV) is standard of care for chronic hypercapnic respiratory failure, but indications, devices, and ventilatory modes are in constant evolution.<br />Research Question: To describe changes in prevalence and indications for NIV over a 15-year period; to provide a comprehensive report of characteristics of the population treated (age, comorbidities, and anthropometric data), mode of implementation and follow-up, devices, modes and settings used, physiological data, compliance, and data from ventilator software.<br />Study Design and Methods: Cross-sectional observational study designed to include all subjects under NIV followed by all structures involved in NIV in the Cantons of Geneva and Vaud (1,288,378 inhabitants).<br />Results: A total of 489 patients under NIV were included. Prevalence increased 2.5-fold since 2000 reaching 38 per 100,000 inhabitants. Median age was 71 years, with 31% being > 75 years of age. Patients had been under NIV for a median of 39 months and had an average of 3 ± 1.8 comorbidities; 55% were obese. COPD (including overlap syndrome) was the most important patient group, followed by obesity hypoventilation syndrome (OHS) (26%). Daytime Paco <subscript>2</subscript> was most often normalized. Adherence to treatment was satisfactory, with 8% only using their device < 3.5 h/d. Bilevel positive pressure ventilators in spontaneous/timed mode was the default mode (86%), with a low use of autotitrating modes. NIV was initiated electively in 50% of the population, in a hospital setting in 82%, and as outpatients in 15%.<br />Interpretation: Use of NIV is increasing rapidly in this area, and the population treated is aging, comorbid, and frequently obese. COPD is presently the leading indication followed by OHS.<br />Trial Registry: ClinicalTrials.gov; No.: NCT04054570; URL: www.clinicaltrials.gov.<br /> (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)

Details

Language :
English
ISSN :
1931-3543
Volume :
158
Issue :
1
Database :
MEDLINE
Journal :
Chest
Publication Type :
Academic Journal
Accession number :
32243941
Full Text :
https://doi.org/10.1016/j.chest.2020.02.064